Pleasant Surprise For InterMune With Early Positive Opinion On Pirfenidone From CHMP
This article was originally published in The Pink Sheet Daily
Executive Summary
With approval in EU nearly certain for IPF drug, InterMune's share price more than doubles.
You may also be interested in...
Biogen Idec Buys Stromedix, Bringing IPF Candidate Full Circle
Started by a former Biogen executive, Stromedix licensed STX-100 from Biogen and developed it into an attractive candidate in an area the reshaped big biotech wants to pursue.
InterMune Gets Ready To Go Commercial With Esbriet Launch In Europe
InterMune plans to launch the first drug for IPF in Europe in September, and has initiated a new Phase III trial with the aim of securing U.S. approval in 2014.
InterMune Gets Ready To Go Commercial With Esbriet Launch In Europe
InterMune plans to launch the first drug for IPF in Europe in September, and has initiated a new Phase III trial with the aim of securing U.S. approval in 2014.